DK3689871T3 - 4,6,7-trisubtitueret 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivat og anvendelse - Google Patents

4,6,7-trisubtitueret 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivat og anvendelse Download PDF

Info

Publication number
DK3689871T3
DK3689871T3 DK18862262.5T DK18862262T DK3689871T3 DK 3689871 T3 DK3689871 T3 DK 3689871T3 DK 18862262 T DK18862262 T DK 18862262T DK 3689871 T3 DK3689871 T3 DK 3689871T3
Authority
DK
Denmark
Prior art keywords
trisubtituated
dihydropyrrol
pyrimidin
pyridin
derivatives
Prior art date
Application number
DK18862262.5T
Other languages
English (en)
Inventor
Shuchun Guo
Fusheng Zhou
Xiang Chen
Jinzhu Zhao
Dong Huang
Jing Xie
Changjiang Qiao
Wan He
Kai Zhang
Xi Chen
Jiong Lan
Original Assignee
Shanghai Haiyan Pharmaceutical Tech Co Ltd
Yangtze River Pharm Group Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Haiyan Pharmaceutical Tech Co Ltd, Yangtze River Pharm Group Co filed Critical Shanghai Haiyan Pharmaceutical Tech Co Ltd
Application granted granted Critical
Publication of DK3689871T3 publication Critical patent/DK3689871T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK18862262.5T 2017-09-28 2018-08-03 4,6,7-trisubtitueret 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivat og anvendelse DK3689871T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710897909 2017-09-28
PCT/CN2018/098481 WO2019062329A1 (zh) 2017-09-28 2018-08-03 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途

Publications (1)

Publication Number Publication Date
DK3689871T3 true DK3689871T3 (da) 2021-12-06

Family

ID=65900477

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18862262.5T DK3689871T3 (da) 2017-09-28 2018-08-03 4,6,7-trisubtitueret 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivat og anvendelse

Country Status (9)

Country Link
US (2) US11174254B2 (da)
EP (1) EP3689871B1 (da)
JP (1) JP6922085B2 (da)
CN (3) CN114478544B (da)
AU (1) AU2018342342B2 (da)
CA (1) CA3077238C (da)
DK (1) DK3689871T3 (da)
SG (1) SG11202002767RA (da)
WO (2) WO2019062329A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
CA3109765A1 (en) * 2019-03-18 2020-09-24 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Btk inhibitor, pharmaceutically acceptable salt, polymorph and application thereof
CN116096369A (zh) * 2020-09-01 2023-05-09 上海海雁医药科技有限公司 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用
CN113061137B (zh) * 2021-04-02 2022-08-02 广西医科大学 含氮杂环衍生物或其药学上可接受的盐和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
MA33909B1 (fr) * 2009-12-23 2013-01-02 Takeda Pharmaceutical Pyrrolidinones accoles en tant d'inhibiteurs de syk
EP2723739B1 (en) * 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
KR102272792B1 (ko) 2013-09-30 2021-07-05 광저우 이노케어 파마 테크 씨오., 엘티디. Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도
BR112016008632A8 (pt) * 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
CN106661039B (zh) * 2014-02-28 2019-09-13 林伯士拉克许米公司 酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途
CN106536503B (zh) * 2014-04-18 2019-09-06 北京澳合药物研究院有限公司 一种酪氨酸激酶抑制剂及其用途
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
FI3236943T3 (fi) * 2014-12-24 2023-04-27 Principia Biopharma Inc Koostumuksia ileo-jejunaaliseen lääkkeenantoon
CN108602805A (zh) * 2015-10-29 2018-09-28 效应治疗股份有限公司 Mnk1和mnk2的异吲哚啉、氮杂异吲哚啉、二氢茚酮和二氢氮杂茚酮抑制剂
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用

Also Published As

Publication number Publication date
AU2018342342B2 (en) 2021-01-07
CN110267954B (zh) 2022-05-10
CN114478544B (zh) 2023-06-16
EP3689871A4 (en) 2020-08-05
AU2018342342A1 (en) 2020-04-16
JP2020535170A (ja) 2020-12-03
CA3077238C (en) 2022-04-12
US11155546B2 (en) 2021-10-26
EP3689871B1 (en) 2021-09-29
CA3077238A1 (en) 2019-04-04
EP3689871A1 (en) 2020-08-05
SG11202002767RA (en) 2020-04-29
CN114478544A (zh) 2022-05-13
US20200223846A1 (en) 2020-07-16
WO2019062328A1 (zh) 2019-04-04
CN110366553B (zh) 2022-04-15
WO2019062329A1 (zh) 2019-04-04
CN110267954A (zh) 2019-09-20
US20200048248A1 (en) 2020-02-13
CN110366553A (zh) 2019-10-22
JP6922085B2 (ja) 2021-08-18
US11174254B2 (en) 2021-11-16

Similar Documents

Publication Publication Date Title
DK3846904T3 (da) 5-morpholin-4-yl-pyrazolo[4,3-b]pyridinderivater
ZA201904737B (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
SG11201912267SA (en) Nicotinamide riboside derivatives and their uses
ZA201706040B (en) Maytansinoid derivatives, conjugates thereof, and methods of use
HK1254654A1 (zh) 4，6-亞嘧啶基衍生物及其用途
DK3359541T3 (da) N-sulfonylerede pyrazol[3,4-b]pyridin-6-carboxamider og fremgangsmåde til anvendelse
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3297637T3 (da) Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf
DK3712152T3 (da) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
DK3371185T3 (da) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
IL253656A0 (en) Mono- and polyazanephthalene modified histories and their use
EP3632907C0 (en) N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
HRP20190013T1 (hr) Derivati 1,2-dihidro-3h-pirolo[1,2 -c]imidazol-3-ona i njihova uporaba kao antibakterijska sredstva
DK3689871T3 (da) 4,6,7-trisubtitueret 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivat og anvendelse
IL251780B (en) Derivatives of 5-(3-hydroxy-propyn-1-yl)-3-(2-amino-pyrimidinyl)-h1-pyrrolo[c-3,2] pyridine and pharmaceutical preparations containing them
DK3481827T3 (da) Imidazo[1,2-a]pyridinderivater, fremgangsmåder til fremstilling og anvendelse deraf
GB201907083D0 (en) 99mtc-labelled isonitrile-containing glucose derivative and preparation method and use
IL263172A (en) The history of three-ring heterocycles, their preparation and use
IL261643B (en) Piperidine derivatives, their preparation and use
RS62819B1 (sr) Derivati aminopiridina i njihova upotreba kao selektivnih alk-2 inhibitora
PT3135110T (pt) Derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processos para a produção e utilização dos mesmos
IL282527A (en) 5-Azaindazole history and their use
IL282526A (en) 5-Azaindazole history and their use
IL274722A (en) History of pyridinones and their use as selective inhibitors of ALK-2
DK3604303T3 (da) Hidtil ukendt pyrrolopyridinderivat, fremgangsmåde til fremstilling heraf og anvendelse deraf